☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
HUTCHMED
HUTCHMED Reports the NMPA’s Acceptance of sNDA for Savolitinib to Treat NSCLC
March 28, 2024
HUTCHMED Receives the Pharmacy and Poisons Board of Hong Kong’s Approval for Elunate (fruquintinib) to Treat Metastatic Colorectal...
January 30, 2024
HUTCHMED Reports NDA Acceptance with Priority Review by the US FDA for Sovleplenib to Treat Primary Immune Thrombocytopenia (PIT)
January 11, 2024
Hutchmed Completes Enrollment for the P-II/III Trial for Fruquintinib + Sintilimab to Treat Renal Cell Carcinoma in China
December 13, 2023
HUTCHMED Reports the NDA Submission of Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
September 29, 2023
HUTCHMED Reports P-III Trial (ESLIM-01) Results of Sovleplenib for Primary Immune Thrombocytopenia in China
August 21, 2023
Load more...
Back to Home